ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SMMT
RDY (64) JAZZ (49) ELAN (45) BMRN (74) ⌘ Pro Terminal →

Summit Therapeutics Inc. (SMMT) — RQD Stock Rating Cockpit

$14.80 -7.67% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.57

Summit Therapeutics Inc. (SMMT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $12.82B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SMMT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SMMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Summit Therapeutics Inc. (NASDAQ: SMMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $14.80 (-7.67% 1D, market cap $12.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SMMT ranks #452 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SMMT compare to RDY and JAZZ in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SMMT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RDY (Dr. Reddy's Laboratories Ltd) holds a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SMMT?
▼

Per SMMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001599298), Summit Therapeutics Inc. generated $3.57B in revenue (+463.7% YoY), -$1.08B in net income, and -$323.6M in free cash flow against $751.2M in total assets and $41.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $14.57 (-1.57%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (8)SEC (14)Macro (5)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$31 Bull$14 Base$11 Bear
📬 FREE SMMT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SMMT)Realized 20D OHLCV Swing Band: ±10.2%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY SMMT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$15.13+4.6% Next Q
Q2 (-2Q)
45
Grade D$15.83-0.4% Next Q
Q3 (-1Q)
43
Grade D$15.77-6.2% Next Q
Current
40
Grade D-$14.80-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SMMT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SMMT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.24) and Max Pain ($15.54) forces dealer call-delta covering toward $30.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SMMT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SMMT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
50.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
26.00>3.0 Fortress Safe
PIOTROSKI F-SCORESOLID CORE (5–6)
5 / 99-Pt Accounting
52-WEEK LASER RANGE16% OF RANGE
L: $12$14.80H: $29
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SMMT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -2.50% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (30)

13/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like SMMT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SMMT)

  • ✓Walkthrough of SMMT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SMMT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -12.84%📐 HORIZONTAL RANGE
2026-11-03O $16.20H $16.20L $14.80C $14.80VOL 3.51M
RES: $20.97SUP: $11.49SMA50: $16.24SMA200: $16.17
$20.19$17.99$15.79$13.59$11.39RES $20.97SUP $11.49$14.802026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SMMT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SMMT Butterfly Map → + Track SMMT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
26.2%/yr Implied 5Y Growth

vs. +463.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SMMT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SMMT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SMMT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SMMT)

Health Care Rank #452 of 1015 ⚔️ RDY vs SMMT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SMMT vs. RDY, JAZZ, ELAN, BMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Summit Therapeutics Inc. (SMMT) ranks #452 by composite RQD confidence (40/100, grade D-) and #87 by equity capitalization ($12.82B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SMMT at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SMMT ACTIVE
Summit Therapeutics Inc.
D- 40/100 — — -35.0% -7.67% $12.82B Benchmark Subject
RDY
Dr. Reddy's Laboratories Ltd
C 64/100 32.8x — 9.9% -0.28% $11.83B /rdy-vs-smmt →
JAZZ
Jazz Pharmaceuticals plc (Ireland)
D 49/100 — — -4.7% -0.71% $14.02B /jazz-vs-smmt →
ELAN
Elanco Animal Health Incorporated
D 45/100 — 55.0% -2.5% +4.51% $11.52B /elan-vs-smmt →
BMRN
BioMarin Pharmaceutical Inc.
B 74/100 31.9x 77.7% 6.0% -1.83% $11.33B /bmrn-vs-smmt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001599298 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Summit Therapeutics Inc. (SMMT) reported GAAP revenue of $3.57B (+463.7% vs. FY2024 revenue of $632.8M , and +109.0% cumulative change since FY2023) , GAAP net income of -$1.08B, operating cash flow of -$322.9M, and free cash flow of -$323.6M (-127.5% YoY). On the balance sheet, SMMT closed FY2025 with $751.2M in total assets against $41.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.57B -$1.08B -$322.9M -$323.6M $751.2M $41.5M
FY2024 (FY) 2024-12-31 $632.8M -$221.3M -$142.1M -$142.2M $435.6M $21.1M
FY2023 (FY) 2023-12-31 $1.71B -$614.9M -$76.8M -$76.8M $7.13B $1.67B

3. SMMT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SMMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Summit Therapeutics Inc. (NASDAQ: SMMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $14.80 (-7.67% 1D, market cap $12.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, SMMT ranks #452 in composite RQD confidence.

How does SMMT compare to RDY and JAZZ in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SMMT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RDY (Dr. Reddy's Laboratories Ltd) holds a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SMMT?

Per SMMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001599298), Summit Therapeutics Inc. generated $3.57B in revenue (+463.7% YoY), -$1.08B in net income, and -$323.6M in free cash flow against $751.2M in total assets and $41.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SMMT trading relative to its 50-day, 200-day, and 52-week technical levels?

SMMT last traded at $14.80 (-7.67% on volume of 3,870,162 shares), positioning the stock -8.87% below its 50-day simple moving average ($16.24) and -8.47% below its 200-day simple moving average ($16.17). Across its 52-week range of $12.07 to $29.23, SMMT sits at the 15.9% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($13.29 to $16.31).

Direct Sub-Reports: SMMT RQD Cockpit SMMT 12M Forecast SMMT Earnings & Move SMMT Dividends & DRIP SMMT Insiders & 13F SMMT Whale Options SMMT Profit Sankey SMMT News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SMMT — Summit Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Summit Therapeutics Inc. (SMMT) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $14.80 (-7.67% 1D, market capitalization $12.82B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -36.3%, and free cash flow yield of -2.50%.
  • Whale 13F & Options Flow (8/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 0.97x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 5/9, and Debt/Equity of 0.06x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Summit Therapeutics Inc. Common Stock (SMMT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B. Reported revenue is — in each of FY 2023, FY 2024, and FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Summit Therapeutics Inc. (SMMT) reported $3.57B in annual revenue (up from $632.8M in FY2024, +463.7% YoY) and -$1.08B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.71B revenue, -$614.9M net income) through FY2025, SMMT scaled operating cash flow to -$322.9M and free cash flow to -$323.6M, backed by $751.2M in total assets against $41.5M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.50% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $12.07 – $29.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -36.3% operating margins and a 0.97x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. An investor should watch for the financing-driven share issuance referenced in the news feed as a potential dilution channel, but the source does not quantify its effect.

  • Key Question #1: Can SMMT sustain or expand its -36.3% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.57B and free cash flow of -$323.6M, how will capital allocation balance growth reinvestment against $41.5M in total debt?
  • Key Question #3: How sensitive is SMMT's 34.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.97x)?

SMMT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Summit Therapeutics Inc. (SMMT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SMMT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SMMT Bull vs. Bear Conversation Board — What's Your Call at $14.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SMMT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SMMT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $18.92 (+18.0%)
📌 Pinned Debate

The forensic balance sheet scores 14 out of 20 with Debt/Equity of 0.06, giving the company low leverage while it funds trial and partn

Here is why I am bullish on SMMT here at $16.03: The forensic balance sheet scores 14 out of 20 with Debt/Equity of 0.06, giving the company low leverage while it funds trial and partnership catalysts.. Compare SMMT's -36.3% operating margin and -35.0% ROIC against the rest of Biotechnology: Pharmaceutical Preparations. As long as cash conversion holds up, dips toward $15.23 are getting bought.

RetailWhale_TX 🐂 BULL

Both sides have a point here — SMMT's 14/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

MU MultipleCompression RQD DEBATE OPENER • Valuation Discipline 🐻 BEARISH 🎯 Target: $13.79 (-14.0%)
Spot @ $16.03

ROIC of -35% and FCF yield of -2.5% show the business is not currently generating cash returns, while a $2B financing points to future

ROIC of -35% and FCF yield of -2.5% show the business is not currently generating cash returns, while a $2B financing points to future dilution.. Look at the math on SMMT: paying 34.0x forward P/E for -35.0% ROIC and -36.3% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $14.11 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%